Quantcast

AxoGen, Inc. Research Submission Selected for Outstanding CTBS Abstract Award at The American Association of Tissue Banks 2012 Annual Meeting

September 8, 2012

The abstract submission titled “Clinical Results from a Multicenter Registry Study on the Use of Processed Nerve Allograft for Sensory, Mixed and Motor Nerve Repairs” was selected for an Outstanding award and poster display at AATB 2012 Annual Meeting.

Alachua, FL (PRWEB) September 07, 2012

AxoGen Inc., Inc. (OTCBB: AXGN), a leader in the science and commercialization of surgical solutions for peripheral nerve repair, announced today that its submission titled “Clinical Results from a Multicenter Registry Study on the Use of Processed Nerve Allograft for Sensory, Mixed and Motor Nerve Repairs” was selected for an Outstanding CTBS Abstract Award and accepted for poster display at the American Association of Tissue Banks 2012 Annual Meeting, Keystone, Colorado, September 8-10.

The abstract reports on findings from the RANGER Registry, an on-going multicenter utilization and outcomes study for the Avance® Nerve Graft, a processed nerve allograft for the repair and reconstruction of peripheral nerve segmental defects, for 66 patients and 92 injuries. Subgroup analysis demonstrated successful recovery in 87% of cases for sensory function and 84% of cases for motor function with no reported graft related complications, tissue rejections or adverse events.

“The RANGER Study is the largest, multicenter observational study in peripheral nerve repair. We are very pleased to see these levels of meaningful recovery across sensory, motor and mixed nerves,” commented Erick DeVinney, Director, Clinical and Translational Sciences for AxoGen, Inc. “The selection by AATB for an Outstanding CTBS Abstract Award speaks to the importance of this study in demonstrating outcomes from peripheral nerve injuries repaired using processed nerve allograft.”

Avance® Nerve Graft is the only commercially available processed nerve allograft for surgically repairing peripheral nerve discontinuities. By eliminating a second surgery to harvest the patient´s own nerve tissue for use in the repair, Avance® Nerve Graft offers surgeons and patients an alternative to traditional autograft nerve repair procedures.

About AxoGen, Inc.

AxoGen (OTCBB: AXGN) is a regenerative medicine company dedicated to advancing the science of peripheral nerve repair and commercializing next generation surgical technologies. The Company´s portfolio of proprietary products and technologies offers new options for surgical nerve repair and reconstruction. Every day, people suffer traumatic injuries and damage caused by disease and prior surgery that impacts the function of their peripheral nerves. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of function and feeling. AxoGen´s products offer a full suite of surgical nerve repair solutions including Avance® Nerve Graft, the only commercially available process nerve allograft nerve for bridging nerve discontinuities of 5mm to 70mm in length, AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves gaps up to 5mm in length, and AxoGuard® Nerve Protector, a bioscaffold used to reinforce a coaptation site, wrap a partially severed nerve or isolate and protect nerve tissue.

AxoGen, Inc. brings the science of nerve repair to life with thousands of surgical implants of AxoGen products and technology performed in hospitals and surgery centers across the United States, including military hospitals serving U.S. service men and women.

AxoGen, Inc. is the parent of its wholly owned operating subsidiary, AxoGen, Inc. Corporation. AxoGen´s principal executive office and operations are located in Alachua, FL. To receive email alerts directly from AxoGen, please click here http://www.axogeninc.com/emailalerts.html .

Cautionary Statements Concerning Forward-Looking Statements

This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management´s current expectations or predictions of future conditions, events or results based on various assumptions and management´s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “may”, “should”, variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product development, product potential or financial performance. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen´s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen´s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/9/prweb9878763.htm


Source: prweb



comments powered by Disqus